The United Kingdom and the United States have announced a key commercial pact that will ensure zero duties on British pharmaceutical exports entering the US market.
Key Provisions of the Accord
As part of the deal, the UK has agreed to boost spending on drugs through the National Health Service (NHS). This commitment ensures that import taxes on these vital products will remain at zero for a duration of three years.
This agreement follows earlier statements to hike tariffs on branded pharmaceutical products, with figures mentioned reaching double the cost.
"This arrangement with the Britain strengthens the international landscape for innovative medicines and establishes much-needed equity to American-British drug exports," a statement said.
Trade Importance
Medicines constitute one of the the United Kingdom's biggest export categories to the America, which is clearly the biggest destination for leading companies like GSK and AstraZeneca.
Export figures show that in the 12 months to the end of the third quarter, the UK exported pharmaceutical products totaling billions to the US. This figure accounted for 17.4% of British export trade in that span.
"This agreement safeguards work, increases funding and facilitates the UK to emerge as a international leader for life sciences," a government official stated.
Specific UK Commitments
The agreement includes several specific commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it judges new medicines to be unaffordable by 25%.
- Higher Drug Budget: There is a aim to raise overall NHS spending on medicines from 0.3 percent of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The percentage pharmaceutical firms must refund to the NHS to prevent overspending will be capped at 15%. In the past, refunds exceeded 20%.
Recent Tensions
The deal follows a protracted tension between the pharmaceutical industry and the UK government over medicine costs and approval rates.
This friction were heightened by assertions that US customers were paying a premium for the same drugs than people in the other developed nations.
Recently, several large drug company projects in the UK have been halted or abandoned, while major investments have been announced toward American operations.
The Science Minister publicly accepted that the NHS needed to invest a greater share on treatments, noting that its budget allocation on drugs had decreased as a percentage of its total funding over the previous ten-year period.
